Omeros Corp (OMER) Stock AnalysisOMEROmeros Corp

Omeros Corporation is a clinical-stage biopharmaceutical company. The Company focuses on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan indications, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Its clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program. Its commercial product, YARTEMLEA, is the approved inhibitor of the lectin pathway of complement. YARTEMLEA is used for the treatment of TA-TMA in adults and in children ages two years and older. YARTEMLEA selectively inhibits MASP-2, blocking pathway activation while preserving classical and alternative complement pathway functions. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Omeros Corp (OMER) is a good buy right now, primarily due to its recent financial turnaround, with a reported net income of $13.23 million for Q2 2026, compared to a net loss of $25.42 million last year. Additionally, the gross margin has significantly improved to 97.20% in Q2 2026, indicating strong operational efficiency. The stock is currently priced at $18.61, which is favorable considering the analyst price target of $33, suggesting a potential upside of approximately 77%. However, a notable risk is the forward P/E ratio of 36.50, indicating that the stock may be overvalued based on future earnings expectations.

7 analysts cover OMER: 6 rate it Buy, 1 Hold and 0 Sell. The average price target is 43.67.